Published in Mol Ther on March 01, 2001
In vitro and in vivo effects of polyethylene glycol (PEG)-modified lipid in DOTAP/cholesterol-mediated gene transfection. Int J Nanomedicine (2010) 1.09
Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One (2012) 1.00
PDX-1 is a therapeutic target for pancreatic cancer, insulinoma and islet neoplasia using a novel RNA interference platform. PLoS One (2012) 0.88
Non-small cell lung carcinoma cell motility, rac activation and metastatic dissemination are mediated by protein kinase C epsilon. PLoS One (2012) 0.87
MDA-7/IL-24 suppresses human ovarian carcinoma growth in vitro and in vivo. Mol Cancer (2007) 0.85
EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2/M cell-cycle arrest and inducing DNA damage. Int J Nanomedicine (2014) 0.84
Targeted cytosine deaminase-uracil phosphoribosyl transferase suicide gene therapy induces small cell lung cancer-specific cytotoxicity and tumor growth delay. Clin Cancer Res (2010) 0.84
Personalized cancer approach: using RNA interference technology. World J Surg (2011) 0.83
A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass nonspecific uptake in vivo. Gene Ther (2010) 0.83
Intravenous delivery of liposome-mediated nonviral DNA is less toxic than intraperitoneal delivery in mice. World J Surg (2005) 0.82
Specific targeting of pancreatic islet cells in vivo by insulin-promoter-driven adenoviral conjugated reporter genes. World J Surg (2006) 0.82
Nonviral delivery for genomic therapy of cancer. World J Surg (2009) 0.81
Targeting of small molecule anticancer drugs to the tumour and its vasculature using cationic liposomes: lessons from gene therapy. Cancer Cell Int (2006) 0.80
Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration. J Nanobiotechnology (2016) 0.78
Reversible masking using low-molecular-weight neutral lipids to achieve optimal-targeted delivery. J Drug Deliv (2012) 0.78
HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration and invasion in lung cancer. Cancer Gene Ther (2015) 0.78
Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications. Pharmaceuticals (Basel) (2012) 0.77
Tumor suppressor gene-based nanotherapy: from test tube to the clinic. J Drug Deliv (2011) 0.77
Safety and in vivo expression of a GNE-transgene: a novel treatment approach for hereditary inclusion body myopathy-2. Gene Regul Syst Bio (2009) 0.76
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer. Mol Ther (2015) 0.76
Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma. Mol Ther (2016) 0.75
Optimization of Non-Viral Gene Therapeutics Using Bilamellar Invaginated Vesicles. J Genet Syndr Gene Ther (2011) 0.75
Identification of Fhit as a post-transcriptional effector of Thymidine Kinase 1 expression. Biochim Biophys Acta (2017) 0.75
Tumor-targeted nanoparticle delivery of HuR siRNA inhibits lung tumor growth in vitro and in vivo by disrupting the oncogenic activity of the RNA-binding protein HuR. Mol Cancer Ther (2017) 0.75
Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature (2000) 32.30
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A (1980) 30.08
A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell (1998) 18.32
Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature (2001) 11.72
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res (1987) 10.80
Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity (Edinb) (2005) 9.85
Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science (1997) 8.43
Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science (1997) 8.24
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med (1998) 7.60
p53: a frequent target for genetic abnormalities in lung cancer. Science (1989) 7.51
The genome of the natural genetic engineer Agrobacterium tumefaciens C58. Science (2001) 6.90
Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. Cell (1996) 6.42
Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature (1984) 6.23
Impaired energy homeostasis in C/EBP alpha knockout mice. Science (1995) 5.68
VT/VF: 60/60 protection. Pacing Clin Electrophysiol (1990) 5.15
Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res (1985) 5.02
Susceptibility-weighted imaging: technical aspects and clinical applications, part 2. AJNR Am J Neuroradiol (2009) 4.93
L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature (1985) 4.66
Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol Cell (2001) 4.58
Susceptibility-weighted imaging: technical aspects and clinical applications, part 1. AJNR Am J Neuroradiol (2008) 4.57
Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature (1985) 4.47
Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci (1992) 4.39
Activation of PPARgamma coactivator-1 through transcription factor docking. Science (1999) 4.33
Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science (1988) 4.26
Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1. Nat Med (2001) 4.19
Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst (2001) 4.14
Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci U S A (1990) 4.06
Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc Natl Acad Sci U S A (2001) 3.96
Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis (2008) 3.77
Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest (1998) 3.51
Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis (2008) 3.42
Cloning and sequence analysis reveal structural variation among related zein genes in maize. Cell (1982) 3.40
Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1. Nature (1998) 3.36
NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl (1996) 3.24
Monocyte-conditioned medium, interleukin-1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro. J Cell Biol (1986) 3.20
Etiology of community-acquired pneumonia in hospitalized patients: a 3-year prospective study in Japan. Chest (1998) 3.15
Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer (1998) 3.12
Molecular genetics of small cell lung carcinoma. Semin Oncol (2001) 3.02
Direct coupling of transcription and mRNA processing through the thermogenic coactivator PGC-1. Mol Cell (2000) 3.00
Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor epsilon 1 subunit. Nature (1995) 2.91
p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J (1992) 2.90
Reactive pseudosarcomatous response in urinary bladder. Urology (1980) 2.89
Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg (2000) 2.88
Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst (1997) 2.83
Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene (2008) 2.83
Assembly of the nuclear transcription and processing machinery: Cajal bodies (coiled bodies) and transcriptosomes. Mol Biol Cell (1999) 2.80
Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res (2001) 2.80
NCI series of cell lines: an historical perspective. J Cell Biochem Suppl (1996) 2.75
Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med (1999) 2.74
Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res (1998) 2.72
Genetic control of diploid recovery after gamma-irradiation in the yeast Saccharomyces cerevisiae. Mutat Res (1980) 2.72
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene (1992) 2.64
Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol (1995) 2.62
Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest (1999) 2.61
Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature (1987) 2.59
Stabilization of interleukin-2 mRNA by the c-Jun NH2-terminal kinase pathway. Science (1998) 2.57
Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol (2003) 2.57
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res (1987) 2.56
bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res (1995) 2.56
Majority logic gate for magnetic quantum-dot cellular automata. Science (2006) 2.51
Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med (1996) 2.51
Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys (1995) 2.50
Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst (2000) 2.45
Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci U S A (1994) 2.43
The DNA sequence and biological annotation of human chromosome 1. Nature (2006) 2.42
HIV-1 infection in commercial plasma donors in China. Lancet (1995) 2.42
C-TAK1 protein kinase phosphorylates human Cdc25C on serine 216 and promotes 14-3-3 protein binding. Cell Growth Differ (1998) 2.39
Chemotherapy for non-small cell lung cancer. BMJ (1995) 2.39
Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol (1997) 2.38
The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex. Mol Cell Biol (1997) 2.35
JNKK1 organizes a MAP kinase module through specific and sequential interactions with upstream and downstream components mediated by its amino-terminal extension. Genes Dev (1998) 2.30
Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene (2007) 2.27
Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg (1995) 2.25
Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res (2000) 2.24
Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene (2001) 2.22
Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev (2000) 2.21
Conservation of autosomal gene synteny groups in mouse and man. Nature (1978) 2.18
Is the sphere organelle/coiled body a universal nuclear component? Dev Genet (1995) 2.17
Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet (1995) 2.15
A new type of glutamate receptor linked to inositol phospholipid metabolism. Nature (1987) 2.15
Estimating the number of people at risk for and living with HIV in China in 2005: methods and results. Sex Transm Infect (2006) 2.15
Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene (2006) 2.14
Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem (1992) 2.14
Deregulated expression of human c-jun transforms primary rat embryo cells in cooperation with an activated c-Ha-ras gene and transforms rat-1a cells as a single gene. Proc Natl Acad Sci U S A (1989) 2.13
Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res (1986) 2.12
Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res (1985) 2.12
Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res (1980) 2.10
Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene (1998) 2.10
Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res (1992) 2.09
Pentalenene synthase. Purification, molecular cloning, sequencing, and high-level expression in Escherichia coli of a terpenoid cyclase from Streptomyces UC5319. Biochemistry (1994) 2.09
Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res (2000) 2.07
High levels of intracellular bombesin characterize human small-cell lung carcinoma. Science (1981) 2.07
Identification of mouse chromosomes required for murine leukemia virus replication. Cell (1977) 2.05
Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut (2001) 2.05
Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J Natl Cancer Inst (1999) 2.03
Cleavage of the site-specific recombination protein gamma delta resolvase: the smaller of two fragments binds DNA specifically. Proc Natl Acad Sci U S A (1984) 2.02
Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci U S A (1990) 2.02
Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet (1982) 2.02